DM
Therapeutic Areas
Incannex Healthcare Pipeline
| Drug | Indication | Phase |
|---|---|---|
| IHL-42X | Obstructive Sleep Apnea | Phase 2/3 |
| Psilocybin-assisted Therapy | Generalized Anxiety Disorder | Phase 2b |
| IHL-675A | Inflammatory Conditions (Rheumatoid Arthritis/Lung Inflammation) | Preclinical |
| CBD-based formulation | Traumatic Brain Injury/Concussion | Preclinical |
| IHL-216A | Neuroprotection | Preclinical |
Leadership Team at Incannex Healthcare
JL
Joel Latham
Chief Executive Officer & Managing Director
SB
Stephen Bond
Chief Financial Officer
DJ
Dr. Julian Kenyon
Medical Director (UK)
PW
Peter Wills AC
Non-Executive Chairman
T(
Terence (Terry) O'Brien
Non-Executive Director
PH
Paul Hopper
Non-Executive Director
PL
Professor Leon Lack
Scientific Advisory Board Member - Sleep Psychology
PD
Professor Danny Eckert
Scientific Advisory Board Member - Sleep Physiology and OSA
DP
Dr. Paul Liknaitzky
Scientific Advisory Board Member - Psychedelic Research Lead